title: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
abstract: BACKGROUND
  Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer.
  
  
  METHODS
  Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed >or= 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by >or= 50% from the pretreatment value. Treatment was composed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later.
  
  
  RESULTS
  Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20%) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia.
  
  
  CONCLUSIONS
  Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20% of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.
authors.affiliation: University of California Davis Cancer Center, Sacramento, CA 95817, USA.
authors.forename: Karen G
authors.initials: KG
authors.lastname: Chee
authors.forename: Jeff
authors.initials: J
authors.lastname: Longmate
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
authors.forename: Gurkamal
authors.initials: G
authors.lastname: Chatta
authors.forename: Jacek
authors.initials: J
authors.lastname: Pinski
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Twardowski
authors.forename: Chong-Xian
authors.initials: CX
authors.lastname: Pan
authors.forename: Angelo
authors.initials: A
authors.lastname: Cambio
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Evans
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.forename: Primo N
authors.initials: PN
authors.lastname: Lara
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*
chemical_list: D000726:Androgen Antagonists; D047428:Protein Kinase Inhibitors; D010767:Phosphorylcholine; C105905:perifosine; D051057:Proto-Oncogene Proteins c-akt